Adaptation of a RAS pathway activation signature from FF to FFPE tissues in colorectal cancer

Simple item page
dc.contributor.authorOmolo, Bernard
dc.contributor.authorYang, Mingli
dc.contributor.authorLo, Fang Yin
dc.contributor.authorSchell, Michael J.
dc.contributor.authorAustin, Sharon
dc.contributor.authorHoward, Kellie
dc.contributor.authorMadan, Anup
dc.contributor.authorYeatman, Timothy J.
dc.date.accessioned2021-05-11T12:27:20Z
dc.date.available2021-05-11T12:27:20Z
dc.date.issued2017
dc.descriptionPaper presented at the 4th Strathmore International Mathematics Conference (SIMC 2017), 19 - 23 June 2017, Strathmore University, Nairobi, Kenya.en_US
dc.description.abstractBackground: The KRAS gene is mutated in about 40 % of colorectal cancer (CRC) cases, which has been clinically validated as a predictive mutational marker of intrinsic resistance to anti-EGFR inhibitor (EGFRi) therapy. Since nearly 60 % of patients with a wild type KRAS fail to respond to EGFRicombination therapies, there is a need to develop more reliable molecular signatures to better predict response. Here we address the challenge of adapting a gene expression signature predictive of RAS pathway activation, created using fresh frozen (FF) tissues, for use with more widely available formalinfixed paraffin-embedded (FFPE) tissues. Methods: In this study, we evaluated the translation of an 18-gene RAS pathway signature score from FF to FFPE in 54 CRC cases, using a head-to- head comparison of five technology platforms. FFPE-based technologies included the Affymetrix Gene Chip (Affy), NanoString nCounter™ (NanoS),Illumina whole genome RNASeq (RNA-Acc), Illumina targeted RNASeq (t-RNA), and Illuminastranded Total RNA-rRNA- depletion (rRNA). Results: Using Affy_FF as the “gold” standard, initial analysis of the 18-gene RAS scores on all 54samples shows varying pairwise Spearman correlations, with (1) Affy_FFPE (r= 0.233, p = 0.090); (2)NanoS_FFPE (r= 0.608, p < 0.0001); (3) RNA-Acc_FFPE (r= 0.175, p = 0.21); (4) t-RNA_FFPE (r=−0.237, p = 0.085); (5) and t-RNA (r= −0.012, p = 0.93). These results suggest that only NanoString has successful FF to FFPE translation. The subsequentremoval of identified “problematic” samples (n= 15) and genes (n= 2) further improves the correlations of Affy_FF with three of the five technologies: Affy_FFPE (r= 0.672, p < 0.0001); NanoS_FFPE (r= 0.738, p < 0.0001); and RNA-Acc_FFPE (r= 0.483, p = 0.002). Conclusions: Of the five technology platforms tested, Nano String technology provides a more faithful translation of the RAS pathway gene expression signature from FF to FFPE than the Affymetrix GeneChip and multiple RNASeq technologies. Moreover, Nano String was the most forgiving technology in the analysis of samples with presumably poor RNA quality. Using this approach, the RAS signature score may now be reasonably applied to FFPE clinical samples.en_US
dc.identifier.urihttp://hdl.handle.net/11071/11820
dc.language.isoenen_US
dc.publisherStrathmore Universityen_US
dc.subjectColorectal canceren_US
dc.subjectFF (fresh-frozen)en_US
dc.subjectFFPE (formalin-fixed, Paraffin embedded)en_US
dc.subjectMicroarrayen_US
dc.titleAdaptation of a RAS pathway activation signature from FF to FFPE tissues in colorectal canceren_US
dc.typeArticleen_US
Files
Original bundle
Now showing 1 - 1 of 1
Thumbnail Image
Name:
Adaptation of a RAS pathway activation signature from FF to FFPE tissues in colorectal cancer.pdf
Size:
76.45 KB
Format:
Adobe Portable Document Format
Description:
Abstract - SIMC Conference paper, 2017
Download
License bundle
Now showing 1 - 1 of 1
Thumbnail Image
Name:
license.txt
Size:
1.71 KB
Format:
Item-specific license agreed upon to submission
Description:
Download
Collections
SIMC 2017